LYME DISEASE. MODERN ISSUE CONDITION
Article PDF (Українська)

Keywords

Lyme borreliosis, features, etiology, epidemiology, clinic, diagnostics

How to Cite

M. Chemych, & I. Lutai. (2020). LYME DISEASE. MODERN ISSUE CONDITION . Eastern Ukrainian Medical Journal, 8(2), 230-241. https://doi.org/10.21272/eumj.2020;8(2):230-241

Abstract

Nowadays Lyme disease (systemic tick-borne borreliosis, Lyme borreliosis) remains one of the most widespread zoonotic diseases with inoculable transmission mechanism, with ixodic ticks as carriers and Borrelia burgdorferi sensu lato as causative agent. The disease is characterized by a staged course and severe damage to various organs and systems.

 In Ukraine, the natural foci of this disease are almost throughout the country. Sumy region occupies a leading place in terms of morbidity. In Ukraine, the most affected regions are: Kyiv (29.00 cases per 100 thousand population), Cherkasy (25.4), Vinnitsa (23.9), Sumy (25.89) regions and Kyiv city (22.54). Lyme disease is mainly registered in the spring-autumn period, this may be due to increased visits to recreation areas and seasonal activity of ticks (May–June, September–October).

Scientific data about etiology, epidemiology, clinical course, diagnostics, therapy and disease preventive measures were analyzed.

It was found that B. burgdorferi s. l. is one of the most widespread agents with inoculable transmission mechanism on the European continent, including Ukraine. There is no single worldwide conception concerning preventive measures, diagnostics and treatment, which necessitates further study of this problem. Detection of antibodies to B. Burgdorferi s. l. in the human blood serum is not an evidence of infection, but testifies previous contact with these pathogens and presence of high risk of Lyme disease development.

To improve the epidemiologic situation concerning Lyme disease it is required to study sites of the disease in Ukraine more thoroughly, to improve epidemiological surveillance system by creating disease spread map for diseases which are transferred by ticks in Sumy region, to plan a series of anti-epidemic and preventive measures, which are of practical use for population, to prevent asymptomatic disease course and chronization.

https://doi.org/10.21272/eumj.2020;8(2):230-241
Article PDF (Українська)

References

1. Steere AC. Lyme disease. N. Engl. J. Med. 1989;321(9):586–596. doi:10.1056/NEJM198908313210906
2. Uchaikin VF, Shamsheva OV. Infektsii y Ditei [Infectious in Children]. M.:Geotar–media, 2015. 387 – 391 р.
3. Steere А, Malawista S, Hardin A. Erythema chronicummigrans and Lyme arthritis. Theen larging clinical spectrum (literature reviewer). Intern. Med. 1977;86(6):685–98.
4. Wormser G, Dattwyler R, Shapiro Е et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis. 2006;43:1089–1134. doi: 10.1086/
5. Anan'eva LP. Lime-borreliosis or ixodid tick-borne borreliosis. Part 1. Etiology, clinic, diagnostics. Infektsii i antimikrobnaia terapiia. 2002;4(2):42–45.
6. Uchaikin VF, Shamsheva OV. Infektsii y Ditei [Infectious in Children]. M.:Geotar–media, 2015. 387 – 391 р.
7. Rogovskyy A, Batool M, Gillis DC, Holman PJ, Nebogatkin IV, Rogovska YV, Rogovskyy MS. Diversity of Borrelia spirochetes and other zoonotic agents in ticks from Kyiv, Ukraine. Ticks Tick Borne Dis. 2017;9(2)404–409. doi: 10.1016/j.ttbdis.2017.12.006.
8. Bush LM, Vazquez-Pertejo MT. Tick borne illness-Lyme disease. Dis Mon. 2018;64(5)195-212. doi: 10.1016/j.disamonth
9. Ministry of health of Ukraine. Guidelines on epidemiology, diagnosis and prophylaxis of ixodic tick borelliosis (Lyme disease) in Ukraine. In: Ministry of health of Ukraine. 2005(18). Retrieved from: https://dnaop.com/html/44267
10. Wormser G, Dattwyler R, Shapiro E et al. The clinical assessment, treatment and prevention of Lyme diseases, human granulocytic, and babesiosis: clinical practice guidelines by the infectious diseases society of America. Clin. Infect. 2006;43:1089-1134. doi: 10.1086/508667
11. Bagautdinova LI, Sarkasian DS, Dudariev MV, Malinin OV, Kustarnikov GK, Shakhov VI, Malinin IY. Clinical polymorphism of disease caused by Borrelia miyamotoi (literature reviewer). Practical medicine. 2013;5(74):125-130.
12. Walter K, Carpi G, Caccone A, Diuk-Wasser M. Genomic insights into the ancient spread of Lyme disease across North America. Nat Ecol Evol. 2017;1(10):1569-1576. Doi: 10. 1038/s41559-17-0282-8.
13. Talaska T, Krause A, Aberer E, Kaiser R. Epidemiological, biological, and ecological aspects of Lyme borreliosis. Focus on Lyme-Borreliosis (literature reviewer). DiaSorin. 2013:5–25.
14. Krause PJ, Narasimhan S, Wormser GP, Barbour AG, Platonov AE, Brancato J, Lepore T, Dardick K, Mamula M, Rollend L, Steeves TK, Diuk-Wasser M, Usmani-Brown S, Williamson P, Sarksyan DS, Fikrig E, Fish D. Tick Borne Diseases Group. Emerg Infect Dis. 2014;20(7):1183-90. doi: 10.3201/eid2007.131587.
15. Szulzyk T, Flisiak R. Lyme borreliosis (literature reviewer). Annals of Parasitologi. 2012;58(2):63-69.
16. Moore A, Nelson C, Molins C, Mead P et al. Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis if Lyme disease, United States. Emerging Infectious Diseases. 2016;22(7):1169-1177. doi: 10.3201/eid2207.151694.
17. Golubovskaia OA, Andreichin MA, Shkruba AV et al, Infektsionnye bolezni [Infectious Diseases]. Кyiv: Meditsina; 2014. 784 p.
18. Shah JS, Crus D, Ward S, Harris NS, Ramasamy R. Development of a sensitive PCR-dot blot assay to supplement serological tests for diagnosing Lyme disease. Eur J Clin Microbiol Infect Dis. 2018;37(4)701-709. doi: 10.1007/s10096-017-3162-x
19. Schwenkenbecher P. Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization. BMC Infect. Dic. 2017;17:90-96. doi: 10.1186/s12879-016-2112-z
20. Shah JS, D'Cruz I, Ward S, Harris NS, Ramasamy R. Development of a sensitive PCR-dot blot assay to supplement serological tests for diagnosing Lyme disease. Eur J Clin Microbiol Infect Dis. 2018;37(4)701-709. doi: 10.1007/s10096-017-3162-x
21. Verhaegh D, Joosten LAB, Oosting M. The Role of Host Immune Cells and Borrelia Burgdorferi Antigens in the Etiology of Lyme. Eur Cytokine Netw. 2017;28(2):70-84. doi: 10.1684/ecn.2017.0396.
22. Bush LM, Vazquez-Pertejo MT. Tick borne illness-Lyme disease. Dis Mon. 2018.;64(5):195-212. doi: 10.1016/j.disamonth.2018.01.007
23. Maccallini P, Bonin S, Trevisan G. Autoimmunity against a lycolytic enzyme as a Possible Cause for Persistent Symptoms in Lyme. Med Hypotheses. 2018;110:1-8. doi: 10.1016/j.mehy.2017.10.024
24. Crossland NA, Alvarez X, Embers ME. Late Disseminated Lyme Disease: Associated Pathology and Spirochete Persistence Posttreatment in Rhesus. Am J Pathol. 2018;188(3):672-682. doi: 10.1016/j.ajpath.2017.11.005
25. Batsiura AV. The problem of Lyme borreliosis in the practice of a clinician. Klinichna immunolohiia. Alerholohiia. Infektolohiia. 2011;4(43):17-25.
26. Gilson J, Khalighi K, Elmi F, Krishnamurthy M, Talebian A, Toor RS. Lyme disease presenting with facial palsy and myocarditis mimicking myocardial infarction. J Community Hosp Intern Med Perspect. 2017;7(6):363-365. doi: 10.1080/20009666.2017.1396170
27. Fu Md J, Bhatta L. Lyme carditis: Early occurrence and prolonged recovery. J Electrocardiol. 2017;(17)30:493-4. doi: 10.1016/j.jelectrocard.2017.12.035
28. Sá MC, Moreira C, Melo C, Sousa Á, Carvalho S. Lyme disease and juvenile idiopathic arthritis. A pediatric case report. Rev Bras Reumatol Engl Ed. 2017;57(6):620-622. doi: 10.1016/j.rbre.2015.09.006.
29. Sowula K, Składzień J, Szaleniec J, Gawlik J. Otolaryngological symptoms in patients treated for tick-borne diseases. Otolaryngol Pol. 2018;72(1):30-34. doi: 10.5604/01.3001.0011.5948
30. Baker PJ. Straight talk about chronic Lyme disease. Am J Med. 2018;131(6):592-594. doi: 10.1016/j.amjmed.2017.11.050
31. Lacout A, El Hajjam M, Marcy PY, Perronne C. The Persistent Lyme Disease: “True Chronic Lyme Disease” rather than “Post-treatment Lyme Disease Syndrome”. J Glob Infect Dis. 2018;10(3):170-171. doi: 10.4103/jgid.jgid_152_17
32. Farshad-Amacker NA. Brainstem abnormalities and vestibular nerve enhancement in acute neuroborreliosis. BMC Res Notes. 2013;6:551. Retrieved from: https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-6-551
33. Lantos PM. Chronic Lyme disease. Infect Dis Clin North Am. 2015;29(2):325-40. doi: 10.1016/j.idc.2015.02.006
34. Shehab N. Emergency department visits for antibiotic-associated adverse events Clin Infect Dis. 2008;47(6):735-43. doi: 10.1086/591126
35. Mygland A, Ljostad U, Fingerle V et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur. J. Neurology. 2009;17(1):8-16. doi: 10.1111/j.1468-1331.2009.02862.x
36. Skogman BH, Sjöwall J, Lindgren PE. The NeBoP score - a clinical prediction test for evaluation of children with Lyme Neuroborreliosis in Europe. BMC Pediatrics. 2015;15:214. doi: 10.1186/s12887-015-0537-y
37. Moore A, Nelson C, Molins C, Mead P et al. Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis if Lyme disease, United States . Emerging Infectious Diseases. 2016;22(7):1169—1177. Retrieved from: https://wwwnc.cdc.gov/eid/article/22/7/15-1694_article
38. Mygland A, Liostad U, Finqerle V, Rupprecht T et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. European Journal of Neurology. 2009;17:8—16. Retrieved from: https://doi.org/10.1111/j.1468-1331.2009.02862.x
39. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis a review. JAMA. 2016; 315(16):1767-77. doi: 10.1001/jama.2016.2884
40. Jakson BS. Assessment new culture method for detection of Borelia species from serum of Lyme disease pations. J Clin. Microbiol. 2014;52(3):721-4. doi: 10.1128/JCM.01674-13
41. Pícha D, Moravcova L, Smiskova D. Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections. Journal of the Neurological Sciences. 2016;368:214-20. doi: 10.1016/j.jns.2016.05.059
42. Cameron JD, Lorraine BJ, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135. doi: 10.1586/14787210.2014.940900
43. Maraspin V, Ruzic-Sabljic E, Strle F. Lyme borreliosis and Borrelia spielmanii. Emerg. Infect. Dis. 2006;12:1177. doi: 10.3201/eid1207.060077
44. Natalie S. Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease - United States. MMWR Morb Mortal Wkly Rep. 2017;66(23):607-609. doi: 10.15585/mmwr.mm6623a3
45. Lim S, Kinjo S. Exacerbation of chronic pain after dental extractions in a patient with post-treatment Lyme disease syndrome. Saudi J Anaesth. 2018;12(1):112-114. doi: 10.4103/sja.SJA_47_17
46. Тseng YJ. Incidence and patterns of extended-course antibiotic therapy in patients evaluated for Lyme disease. Clin Infect Dis. 2015;61(10):1536-42. doi: 10.1093/cid/civ636
47. 16 Conférence de consensus en therapeutique anti-infectieuse. Borréliose de Lyme: démarches diagnostiques, thérapeutiques et préventives (literature reviewer). Medecine et Maladies Infectieuses. 2007;37(4):187—93.
48. Koedel U, Fingerle V. Lyme neuroborreliosis - epidemiology, diagnosis and management. Nat Rev Neurol. 2015;11(8):446-56. doi: 10.1038/nrneurol.2015.121
49. Patrick DM. Lyme disease diagnosed by alternative methods: a phenotype similar to that of chronic fatigue syndrome. Clin Infect Dis. 2015;61(7):1084-91. doi: 10.1093/cid/civ470
50. Saccomanno SJ, Hrelic DA. Recognizing and treating Lyme disease. Nurse Pract .2018;43(8):13-21. doi: 10.1097/01.NPR.0000541469.54290.00
51. Middelveen MJ,. Sapi E, Burke J., Filush KR, Fesler MC, Stricker RB. Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease. Healthcare (Basel). 2018;6(2):33. doi: 10.3390/healthcare6020033
52. Torbahn G, Hofmann H, Allert R. , Freitag MH. Efficacy and safety of pharmacological agents in the treatment of erythema migrans in early Lyme borreliosis - systematic review protocol. Systematic Reviews. 2016;5(73). doi: 10.1186/s13643-016-0251-3
53. Briciu VT, Flonta M, Tatulescu DF, Meyer F. Clinical and serological one-year follow-up of patients after the bite of Ixodes ricinus ticks infected with Borrelia burgdorferi sensu lato. Infectious Diseases. 2017;49(4):277-285. doi: 10.1080/23744235.2016.1258488
54. Stricker RB, Johnson L. Lyme disease vaccination: safety first. Lancet Infect Dis. 2014;14(1):12. Retrieved from: https://www.lymedisease.org/lyme-disease-vaccine/
55. Wills AB, Spaulding AB, Adjemian J, Prevots DR, Turk SP, Williams C, Marques A. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis. 2016;62(12):1546-1551. doi: 10.1093/cid/ciw189.
56. Žákovská, A, Janeček J, Nejezchlebová H, Kučerová HL. Pilot study of ixodes ricinus ticks preference for human abo blood groupsusing a simple in vitro method. Annals of Agricultural and Environmental Medicine. 2018;25(2):326-328. doi: 10.26444/aaem/85167
57. Cutler SJ, Rudenko N, Golovchenko M, Cramaro WJ, Kirpach J, Savic S, Christova I. Diagnosing Borreliosis. Vector-Borne and Zoonotic Diseases. 2017;17(1):2-11. doi: 10.1089/vbz.2016.1962
58. Lutai I, Chemych M, Sinuyka V. Lyme disease dissemination in Ukraine. Medicina. 2020;56(1):241
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.